Funding
← Back to your selection

British Business Bank

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026

British Business Bank is the UK’s economic development bank, supporting business access to finance through investment programmes, funds and financing partners.

Its Future Fund: Breakthrough programme, delivered by British Patient Capital, co-invests with private investors in later-stage, R&D-intensive UK companies. It targets technologies such as quantum computing, cleantech and life sciences, where development requires substantial capital.

Applications to that programme come from a qualifying sponsor investor, rather than directly from the company. The published criteria require a round of at least £30 million, with the programme contributing no more than 30% on the sponsor investor’s terms.

Sources
Rounds participated in
6
Confirmed lead rounds
1
4 roles undisclosed
New companies
6
First participation on record · 0 follow-on
Funding in participating rounds
$675M
5 disclosed · full round size, not this investor’s share

By stage

Series C+3
Series B2
Series A1

By primary sector

Biotech6

By country

United Kingdom5
United States1

Rounds

6 in this selection
Microbiotica

Microbiotica develops oral medicines made from selected live bacteria for inflammatory diseases and cancer treatment.

£36MSeries C first close
Lead
OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C
Participant
IMU Biosciences

Profiles human immune systems using multi-omic analysis and machine learning for disease research.

$53MSeries A
Role not disclosed
Nuclera

Provides rapid access to functional proteins through benchtop eProtein Discovery System

$12MSeries C+
Role not disclosed